share_log

Nova Mentis Announces Change of Directors

Nova Mentis Announces Change of Directors

Nova Mentis宣布更换董事
newsfile ·  02/26 21:30

Vancouver, British Columbia--(Newsfile Corp. - February 26, 2024) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company") announces the appointment of Steve Loutskou to the Company's Board of Directors, effective February 23, 2024.

不列颠哥伦比亚省温哥华--(Newsfile Corp.-2024 年 2 月 26 日)- Nova Mentis Life Science Corp.(CSE:NOVA)(FSE:HN3Q)(场外交易代码:NMLSF)(“NOVA” 或 “公司”) 宣布任命 Steve Loutskou 为公司董事会成员,自 2024 年 2 月 23 日起生效。

Mr. Loutskou, a seasoned serial entrepreneur, boasts a career spanning over 20 years, marked by numerous success stories. From the initiation of early-stage start-ups to steering them through mature commercialization phases, he has demonstrated exceptional skills in navigating the intricate landscape of financing. With two decades of experience in business management, operations, and financing, he has garnered a wealth of experiences spanning various sectors of industry.
A trailblazer in innovative ventures, Mr. Loutskou's strategic vision and financial acumen have not only accelerated start-ups to success but also attracted substantial investment. His continued influence remains pivotal in shaping the future of business through insightful strategies and adept financial management.

Loutskou先生是一位经验丰富的连续创业者,拥有超过20年的职业生涯,并有许多成功案例。从创办早期初创企业到引导他们进入成熟的商业化阶段,他在驾驭错综复杂的融资格局方面表现出了非凡的技能。凭借二十年的企业管理、运营和融资经验,他在各个行业积累了丰富的经验。
作为创新企业的开拓者,Loutskou先生的战略愿景和财务敏锐度不仅加速了初创企业走向成功,还吸引了大量投资。他的持续影响力对于通过富有洞察力的战略和熟练的财务管理塑造业务的未来仍然至关重要。

Derek Ivany, Chairman of the Company, stated: "I have had the distinct honor of collaborating with Steve across multiple projects, notably in the triumphant revitalization of a plant-based enterprise. I eagerly anticipate joining forces with Steve again to pioneer ground-breaking strategies for Nova, aimed at elevating our business operations."

公司董事长德里克·伊万尼表示:“我非常荣幸能与史蒂夫合作开展多个项目,特别是在成功振兴一家植物基企业方面。我热切期待再次与Steve联手,为Nova开创性战略,旨在提升我们的业务运营。”

About Nova Mentis Life Science Corp.

关于 Nova Mentis 生命科学公司

Nova Mentis Life Science Corp. is a Canadian-based biotechnology company and global leader in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. Nova is the first biotech company to achieve orphan drug designation in both the United States and European Union for the use of psilocybin in the treatment of fragile X syndrome (FXS).

Nova Mentis Life Science Corp. 是一家总部位于加拿大的生物技术公司,在开发神经炎症性疾病诊断和基于迷幻药的疗法方面处于全球领先地位。Nova是第一家因使用迷幻药治疗脆性X综合征(FXS)而在美国和欧盟获得孤儿药认定的生物技术公司。

NOVA's goal is to diagnose and treat debilitating chronic conditions that have unmet medical needs, such as autism spectrum disorder (ASD) and FXS.

NOVA的目标是诊断和治疗医疗需求未得到满足的使人衰弱的慢性病,例如自闭症谱系障碍(ASD)和FXS。

For further information on the Company, please visit or email info@novamentis.ca.

有关该公司的更多信息,请访问或发送电子邮件至 info@novamentis.ca。

On Behalf of the Board

代表董事会

Will Rascan, President & CEO
Nova Mentis Life Science Corp.

总裁兼首席执行官威尔·拉斯坎
Nova Mentis 生命科学公司

Phone: 778-819-0244
Toll Free: 1-833-542-5323

电话:778-819-0244
免费电话:1-833-542-5323

Twitter: @novamentislsc
Instagram: @novamentislsc
Facebook: @novamentislsc

推特:@novamentislsc
Instagram:@novamentislsc
脸书:@novamentislsc

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

加拿大证券交易所及其市场监管机构(该术语在加拿大证券交易所的政策中定义)均不对本新闻稿的充分性或准确性承担责任。

This news release contains statements that constitute "forward-looking statements." Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause Nova Mentis Life Science's actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur.

本新闻稿包含构成 “前瞻性陈述” 的陈述。此类前瞻性陈述涉及已知和未知的风险、不确定性和其他因素,这些因素可能导致Nova Mentis Life Science的实际业绩、业绩或成就或行业发展与此类前瞻性陈述所表达或暗示的预期结果、业绩或成就存在重大差异。前瞻性陈述是不是历史事实的陈述,通常以 “期望”、“计划”、“预期”、“相信”、“打算”、“估计”、“项目”、“潜力” 和类似表述来识别,或者事件或条件 “将”、“会”、“可能” 或 “应该” 发生。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发